Ixaka (formerly Rexgenero) is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease. Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders. Ixaka has offices in London, UK, with R&D and manufacturing operations in Seville, Spain and Paris, France, and additional manufacturing capability in Frankfurt, Germany.
